Development of the Lee Symptom Scale-Skin Sclerosis for chronic GVHD-associated sclerosis
- PMID: 39808799
- PMCID: PMC11952005
- DOI: 10.1182/blood.2024027334
Development of the Lee Symptom Scale-Skin Sclerosis for chronic GVHD-associated sclerosis
Abstract
Sclerosis is a highly morbid manifestation of chronic graft-versus-host disease (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome (PRO) measure for cGVHD-associated sclerosis is essential to advance therapeutic trials. We aimed to develop a PRO for adults with cGVHD-associated sclerosis and evaluate and refine its content validity. Adults aged ≥18 years with cGVHD-associated sclerosis participated in semistructured interviews to identify salient symptoms and functions. Sclerosis-relevant symptoms and functions from existing PROs were also used to prompt discussion of topics not spontaneously mentioned. Symptoms and functions (subcodes) of importance were clustered and mapped to overarching domains (codes) using inductive analysis, and candidate items were developed. Cognitive interviews were used to evaluate content validity of the items, response options, recall period, and respondent instructions. Thirty-six open-ended interviews, conducted to saturation, revealed the breadth of the patient experience with cGVHD-associated sclerosis including 5 overarching domains: (1) skin changes, (2) symptoms, (3) emotional and social functioning, (4) mobility restrictions, and (5) activity limitations. A pool of 54 items was tested and iteratively refined through cognitive debriefing interviews (n = 25). Phrasing changes were made to improve relevance and comprehension. One item was removed, and 2 items were added to address respondent feedback, resulting in 55 items. Results support the relevance, comprehensibility, and comprehensiveness of the provisional Lee Symptom Scale-Skin Sclerosis. Concept elicitation and cognitive interviewing have informed the development of the Lee Symptom Scale-Skin Sclerosis. Psychometric testing and determination of minimal clinically important differences are underway in an external cohort to validate the PROs.
Conflict of interest statement
Conflict-of-interest disclosure: S.J.L. has received consulting fees from Mallinckrodt, Equillium, Kadmon, Novartis, Sanofi, and Incyte; research funding from AstraZeneca, Pfizer, Sanofi, and Syndax; drug supply from Janssen; is on clinical trial steering committees for Incyte and Sanofi; and is on the board of directors of the National Marrow Donor Program (uncompensated). The remaining authors declare no competing financial interests.
Comment in
-
LSS-Skin Sclerosis: key addition to cGVHD assessments.Blood. 2025 Mar 20;145(12):1234-1235. doi: 10.1182/blood.2025028352. Blood. 2025. PMID: 40111336 No abstract available.
References
-
- Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565–2579. - PubMed
-
- Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the bone marrow transplant survivor study. Blood. 2004;104(6):1898–1906. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous